Die Impfprävention HPV-assoziierter Neoplasien – eine Zusammenfassung der deutschen S3-Leitlinie

Schlüsselwörter

Prophylaktische HPV-Impfung - S3-Leitlinie - Kurzfassung - HPV-Management Forum

Keywords

vaccination - German evidence-based medicine guideline - short-version - HPV-Management Forum

Literatur

• 1 Arbeitsgruppe HPV-Management-Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. . Impfprävention HPV-assoziierter Neoplasien. S3-Leitlinie der Arbeitsgruppe HPV-Management-Forum der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V.  Chemother J. 2008;  17 128-171
• 2 Centers for Disease Control. http://www.cdc.gov/vaccinesafety/vaers/gardasil.htm (Stand: 06. August 2009)
• 3 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V .Interdisziplinäre S2k-Leitlinie für die Prävention, Diagnostik und Therapie der HPV-Infektion 2008 und präinvasiver Läsionen des weiblichen Genitale. AWMF. 015/027: 1-63
• 4 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V .Stellungnahme zur HPV-Impfung:. http://www.dggg.de/_download/unprotected/dggg_hpv_stm.pdf (Stand 18. August 2009)
• 5 Deutscher Bundestag .Antwort der Bundesregierung auf die Kleine Anfrage von […] Bündnis90/Die Grünen, 16/9302, 13.06.2008. http://www.bundestag.de/presse/hib/2008_06/2008_173/11.html (Stand: 06. August 2009)
• 6 European Medicines Agency .Gardasil, European Public Assessment Report, EPARs for authorised medicinal products for human use 2006, Revision 4, Published 07/09/07. http://www.emea.europa.eu/humandocs/Humans/EPAR/gardasil/gardasil.htm (Stand: 3.8.2009)
• 7 European Medicines Agency .Cervarix, European Public Assessment Report, EPARs for authorised medicinal products for human use 2007, Published 03/10/2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm (Stand: 3.8.2009)
• 8 Fairley C K, Hocking J S, Gurrin L C. et al . Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.  Sex Transm Infect. 2009;  85 499-502
• 9 Fife K H, Wheeler C M, Koutsky L A. et al . Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.  Vaccine. 2004;  22 2943-52
• 10 FUTURE II STUDY GROUP . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.  N Engl J Med. 2007;  356 1915-1927
• 11 Garland S M, Hernandez-Avila M, Wheeler C M. et al . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.  N Engl J Med. 2007;  356 1928-1943
• 12 GlaxoSmithKline .Fachinformation Cervarix, September 2007. http://www.fachinfo.de/data/fi/jsearch?praep (Stand: 03.08.2009)
• 13 Harper D M, Franco E L, Wheeler C M. et al . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.  Lancet. 2004;  364 1757-1765
• 14 Harper D M, Franco E L, Wheeler C M. et al . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: followup from a randomised control trial.  Lancet. 2006;  367 1247-1255
• 15 Jahn I, Eberle A, Niehues C. et al .Gesundheitsberichterstattung des Bundes, Gebärmuttererkrankungen. Heft 37. Robert Koch-Institut; 2007
• 16 Joura E A, Leodolter S, Hernandez-Avila M. et al . Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.  Lancet. 2007;  369 1693-1702
• 17 Koutsky L A, Ault K A, Wheeler C M. et al . A controlled trial of a human papillomavirus type 16 vaccine.  N Engl J Med. 2002;  347 1645-1651
• 18 Mao C, Koutsky L A, Ault K A. et al . Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.  Obstet Gynecol. 2006;  107 18-27
• 19 Munoz N, Bosch F X, de Sanjose S. et al . Epidemiologic classification of human papillomavirus types associated with cervical cancer.  N Engl J Med. 2003;  348 518-527
• 20 Paavonen J, Jenkins D, Bosch F X. et al . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.  Lancet. 2007;  369 2161-2170
• 21 Parkin D M. The global health burden of infection-associated cancers in the year 2002.  Int J Cancer. 2006;  118 3030-3044
• 22 Parkin D M, Bray F. The burden of HPV-related cancers.  Vaccine. 2006;  24 S11-S25
• 23 Perrin M, Melinand C, Darras A. Survey of European women's intention to undergo cervical smear testing.25th International Papillomavirus Conference (IPVC). Malmö, Sweden, May 8-14, 2009. 
• 24 Robert Koch-Institut . Epidemiologisches Bulletin. 2009;  32 319-338
• 25 Sanofi Pasteur MSD .Fachinformation Gardasil, August 2007. http://www.fachinfo.de/data/fi/jsearch?praep (Stand: 03.08.2009)
• 26 Slade B A at al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant.  Vaccine JAMA. 2009;  302 750-757
• 27 Statistisches Bundesamt .Gesundheitswesen, Todesursachen in Deutschland 2004. Fachserie 12 / Reihe 4,. Statistisches Bundesamt; 2005
• 28 Villa L L, Costa R L, Petta C A. et al . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial.  Lancet Oncol. 2005;  6 271-278
• 29 Villa L L, Costa R L, Petta C A. et al . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.  Br J Cancer. 2006;  95 1459-1466
• 30 Walboomers J M, Jacobs M V, Manos M M. et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12-19